Emerging Markets

Will this be the first of many biosimilars to hit the Indian market?

Ranbaxy launches India’s first Remicade biosimilar

By Zachary Brennan

Ranbaxy Laboratories has launched the monoclonal antibody Infimab, the first Remicade (Infliximab) biosimilar, in India -- which is the first what could be a few home-grown biosimilar launches.  

Follow us


View more